Articles by tag: clinical-trials

Survodutide trials: failure or effectiveness in weight loss?

Phase 3 SYNCHRONIZE-1 analysis: weight loss 13-16.6%, but 19% discontinuations due to side effects. Is it worth the risk? Read the full review.

EMA Advisory Meeting on Clinical Trials 2026: New Rules

EMA will hold a meeting on clinical trials of innovative therapies in June 2026. New approaches to ATMP study design, RWE and CMC. Learn how the changes will affect the pharmaceutical industry.

Survodutide in obesity: 13% efficacy in phase 3

The new dual agonist Survodutide showed 13% weight reduction in patients with obesity without diabetes. Learn about the mechanism of action, side effects, and prospects of the drug.

Mechanism linking obesity to chronic inflammation: the role of NLRP3

Scientists have found a mechanism how obesity activates the NLRP3 inflammasome, causing inflammation. The discovery leads to new drugs against diabetes. Read in analytics.

Evidence-based cosmetology: why K-beauty chooses science

Kara Clinical bets on evidence-based cosmetology with Eurofine. Find out why home LED and RF devices win over marketing. Read the analysis.

A New Look at Alzheimer's Disease: Roche Tests Spinal ASO Therapy

Roche has initiated Phase I trials of intrathecal ASO against ApoE for early Alzheimer's disease. Why this is a revolution, who will benefit, and hidden risks. Read the analysis.

VERVE-102 gene editing reduces cholesterol by 62% — analysis

Phase 1 results of VERVE-102: sustained LDL-C reduction up to 62% in patients with hypercholesterolemia. Analysis of market implications and forecasts. Read more.

MitoQ: study of its effect on aging — a new standard?

Analysis of the clinical study of the antioxidant MitoQ and the epigenetic clock LinAge3: who benefits from the race for biological rejuvenation and what are the hidden risks. Learn the details.

Safe epilepsy treatment for pregnant women: K.Vita study

Learn how coconut-derived decanoic acid could replace dangerous epilepsy drugs for pregnant women. K.Vita study launch — details and forecasts.

Hepatitis C cocktail: cure in 7–8 weeks

The combination of bemnifosbuvir and ruzasvir reduces the treatment course for hepatitis C from 12 to 7–8 weeks. Learn about trial results and benefits of the new regimen.

Error in the study of cardiac monitors: analysis of BIO|GUARD-MI

How the Danish national healthcare system broke the design of the BIO|GUARD-MI clinical trial. Learn about the hidden causes of failure and consequences for the market. Read the analysis.

mRNA vaccine Moderna against influenza: trials completed

mRNA vaccine Moderna against influenza outperformed traditional vaccines in a trial with 40,000 participants. Learn how this will change the market and when to expect the FDA decision.

Dual-action CAR-T: 100% remission in myeloma at ISCT 2026

ISCT 2026 data analysis: CAR-T therapy TPST-2003 showed complete response in all naive patients. Learn why this is a breakthrough, not an illusion, and what risks are hidden.

J&J Ottava robot: first clinical trials successfully completed

J&J's surgical robot Ottava has passed first clinical trials in bariatric surgery. Learn about the advantages of the innovative system and its impact on the robotic surgery market.

MitoQ and Healthy Aging: NUS Medicine Study

NUS Medicine and MitoQ study the effect of mitochondrial antioxidant on biological aging. Learn about the results of LinAge3 trials and forecasts for the anti-aging market.

Gedatolisib: Phase 3 success in PIK3CA-mutated cancer

Gedatolisib met the endpoint in the VIKTORIA-1 study, surpassing the standard of care. Learn how this will change the market. Read the detailed analysis.

M&A in Pharmaceuticals: Deal Boom Due to AI Drug Development

Big Pharma spends billions on buying AI startups to shorten the R&D cycle. Learn how AI is changing the M&A market. Detailed analysis.